GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolase Inc (FRA:BTH0) » Definitions » Cyclically Adjusted Price-to-FCF

Biolase (FRA:BTH0) Cyclically Adjusted Price-to-FCF : (As of May. 14, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Biolase Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Biolase Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Biolase's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolase Cyclically Adjusted Price-to-FCF Chart

Biolase Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biolase Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biolase's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, Biolase's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biolase's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biolase's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biolase's Cyclically Adjusted Price-to-FCF falls into.



Biolase Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Biolase's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Biolase's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.663/129.4194*129.4194
=-0.663

Current CPI (Dec. 2023) = 129.4194.

Biolase Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -694.667 99.695 -901.789
201406 -34.667 100.560 -44.616
201409 -1,444.000 100.428 -1,860.855
201412 -1,202.500 99.070 -1,570.882
201503 -1,410.000 99.621 -1,831.754
201506 -684.800 100.684 -880.244
201509 -843.800 100.392 -1,087.782
201512 -773.000 99.792 -1,002.493
201603 -918.600 100.470 -1,183.280
201606 -296.000 101.688 -376.722
201609 -308.600 101.861 -392.091
201612 -830.000 101.863 -1,054.538
201703 -996.600 102.862 -1,253.904
201706 -1,106.200 103.349 -1,385.244
201709 -480.667 104.136 -597.371
201712 -504.286 104.011 -627.475
201803 -493.125 105.290 -606.138
201806 -384.250 106.317 -467.747
201809 -240.500 106.507 -292.239
201812 -440.125 105.998 -537.376
201903 -557.750 107.251 -673.038
201906 -168.222 108.070 -201.455
201909 -147.333 108.329 -176.016
201912 -387.909 108.420 -463.041
202003 -288.385 108.902 -342.719
202006 -312.400 108.767 -371.717
202009 -54.152 109.815 -63.819
202012 -28.795 109.897 -33.910
202103 -101.222 111.754 -117.222
202106 -52.717 114.631 -59.518
202109 -51.311 115.734 -57.378
202112 -49.541 117.630 -54.506
202203 -121.919 121.301 -130.079
202206 -106.787 125.017 -110.548
202209 -122.579 125.227 -126.683
202212 -73.256 125.222 -75.712
202303 -17.784 127.348 -18.073
202306 -6.639 128.729 -6.675
202309 -2.202 129.860 -2.195
202312 -0.663 129.419 -0.663

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biolase  (FRA:BTH0) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Biolase Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Biolase's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biolase (FRA:BTH0) Business Description

Traded in Other Exchanges
Address
27042 Towne Centre Drive, Suite 270, Lake Forest, CA, USA, 92610
Biolase Inc is a US-based medical device company. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.

Biolase (FRA:BTH0) Headlines

No Headlines